FDA Regulation of Artificial Intelligence/ Machine Learning

Actions Panel

FDA Regulation of Artificial Intelligence/ Machine Learning

AI/ ML will revolutionize medicine by making diagnosis and treatment more accessible and more effective.

When and where

Date and time

Location

Online

Refund Policy

Contact the organizer to request a refund.
Eventbrite's fee is nonrefundable.

About this event

  • 1 hour
  • Mobile eTicket

AI/ ML will revolutionize medicine by making diagnosis and treatment more accessible and more effective. FDA has regulated medical device software by means of regulation and guidance for years, however, AI/ML programs fall outside the scope of these regulations and guidance. This happens because FDA approves the final, validated version of the software. The point of AI/ML is to learn and update the following deployment using real-world data to improve performance. Thus the field version of the software is no longer the validated approved version.

This training will address the current regulatory requirements, how they don’t control AI/ML adequately, and approaches FDA is considering for regulation in the near future. Development personnel should understand these concepts because, with some modifications, they will become regulations.

It is not clear how to get AI/ML programs approved. Following a discussion of possible future regulation, we will discuss, based on recently approved De Novo applications, how to get your AI/ML program approved now.

Necessary submission documentation will be explained.

This webinar is not a programming course but will explain the present and future regulatory requirements for AI/ML. Attendees will receive a multipage outline and checklist

What you'll learn:-

  • Total product life cycle approach to AI/ ML design
  • Application of FDA software Pre Cert program to AI/ ML
  • FDA discussion paper on AI/ML
  • Database management
  • QC of datasets
  • Algorithm updating
  • Reference standard development
  • Standalone performance testing
  • Clinical performance testing
  • Data Enrichment
  • Emphasis on “explainability”
  • Additional labeling requirements
  • Cybersecurity

Why should you attend:-

It is not clear how to get AI/ML programs approved. The current regulatory requirements don’t control AI/ML adequately.

We will discuss the approaches FDA is considering for regulation in the near future and how to get your AI/ML program approved by FDA now. Necessary submission documentation will be explained

Attendees will receive a multipage outline and checklist.

Who should attend:-

  • Software Engineers
  • Engineers
  • Regulatory personnel
  • Quality Assurance personnel
  • Marketing
  • Management